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The dynamics of kidney 
donation: Viewpoints from the 
donor, the recipients, and the 
transplant team
A Maiorano1 and FP Schena1
Living kidney transplantation has become increasingly widespread 
to reduce organ shortage. Very few studies have prospectively 
investigated the donor’s long-term risks.  Living donation is a 
complex medical decision in which different actors are involved. This 
therapeutic option needs educational programs for potential donors, 
recipients, and transplant professionals to make them aware of the 
possible risks and benefits.  It is important to fully exploit living-
donor kidney transplantation.
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The ﬁrst successful living-donor kidney 
transplant was performed about 50 years 
ago. Since then, living kidney transplan-
tation has become increasingly wide-
spread1 and has helped reduce organ 
shortage. The advantages of living- 
versus cadaveric-donor transplantation 
are now readily apparent, as the former 
is associated with a shorter time to 
transplantation and results in a better 
long-term graft and patient survival.2
Although rates of living kidney trans-
plantation are increasing worldwide, in 
some areas it still lags behind. There are 
several likely reasons for this: restrictive 
laws, negative attitudes toward living 
donation, lack of organization, and local 
practice. Although many guidelines 
for living-donor evaluation have been 
produced, at the present, very few stud-
ies have prospectively investigated 
the long-term risks to living kidney 
donors.3 In fact, although we know for 
certain that the major short-term risk 
for living donors is low, the long-term 
risk of kidney failure and cardiovascular 
disease is less clear. The cardiovascular 
risk, in particular, needs further atten-
tion in the light of recent population-
based observations that even a small 
reduction in kidney function results in 
a signiﬁcant increase in cardiovascular 
morbidity and mortality.4 Virtually all 
of the studies focusing on the long-term 
outcomes in donors are retrospective, 
many with incomplete follow-up, and 
therefore these studies could be subject 
to selection bias that may signiﬁcantly 
limit their interpretability. Most stud-
ies are underpowered to detect clinically 
meaningful diﬀerences between donors 
and control groups. Many studies com-
pare donors with the general popula-
tion, but donors are screened to be 
healthier than the general population, 
and this may not be a valid comparison 
group. Diﬃculties in measurement of 
blood pressure and renal function may 
underestimate the impact of donation 
on these outcomes. Several studies have 
identiﬁed possible risk factors for devel-
opment of hypertension, proteinuria, 
and end-stage renal disease, but poten-
tial vulnerability factors in donors have 
not been well explored, and there is a 
paucity of data on cardiovascular risk 
factors in donors. Moreover, medical 
exclusion criteria are probably diﬀerent 
between diﬀerent centers, and this may 
also aﬀect outcome.5 Thus, living kidney 
donation is a complex medical decision 
in which several aspects should be dis-
cussed by three diﬀerent players around 
a circular and not a rectangular table 
(Figure 1). We consider this very impor-
tant from a psychological point of view, 
because every player must assume equal 
responsibility in the decision-making 
process. The interaction between the 
three groups is complex: the donor’s 
physician needs to protect the patient; 
the donor wishes to see his or her loved 
one healthy again but may be afraid of 
surgery; and the patient wishes to come 
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oﬀ dialysis but not to harm the donor 
in doing so. In a new report by Young 
et al.6 (this issue), a clearer picture of 
this complex interaction among poten-
tial donors, potential recipients, and the 
transplant professionals is displayed. 
The authors suggest that there is a ten-
dency in medical teams to protect the 
donor’s outcome, preferring cadaveric 
transplantation. Many patients on the 
waiting list are willing to accept a living 
kidney donor, but they are often hesi-
tant to ask or discuss the issue with their 
potential donors.7 On the other hand, 
recipients can be excessively cautious 
with regard to donor risk, in both their 
relationship with the potential donor 
and their personal understanding of 
chronic illness.8
On the contrary, potential donors 
could get carried away by enthusiasm 
about the beneﬁt to their relative, under-
estimating risks in both short- and long-
term outcome.7 With this in mind, the 
transplant community has developed a 
fundamental set of principles to guide 
the living-donation process.9 First of 
all, the needs of transplant recipients do 
not outweigh the priority of the long-
term health of organ donors. Thus, both 
donor and recipient have to be evaluated 
carefully, not only from a medical point 
of view, but also speciﬁcally consider-
ing the psychological proﬁle. The person 
who gives consent to be a donor should 
be competent, willing to donate, free of 
coercion, medically and psychosocially 
suitable, fully informed of the risks and 
beneﬁts to himself or herself as a donor, 
and fully informed of the risks, beneﬁts, 
and alternative treatment available to 
the recipient. The beneﬁts to both donor 
and recipient must outweigh the risks 
associated with the donation and trans-
plantation of the living-donor organ. 
Before donation, the live kidney donor 
must receive a complete medical and 
psychosocial evaluation, undergo an 
appropriate informed-consent process, 
and be capable of understanding the 
information presented in that process to 
make a voluntary decision. At all stages 
of the evaluation and transplantation 
process, the donor is as legitimately con-
sidered to be a patient as the transplant 
recipient and thus should be aﬀorded the 
same level of care and the same protec-
tions against undue risks. At this point it 
appears clear that the risk proﬁle and its 
acceptance could be an important step 
in the living-donation process.
Many authors have tried to investi-
gate the behavior of potential donors, 
recipients, and transplant professionals 
(nephrologists, surgeons, living-kid-
ney-donor coordinators, and social 
workers).7,8,10 Usually, the medical team 
appears to be more conservative, par-
ticularly when the donor’s risk proﬁle 
is uncertain. On the other hand, it is 
possible that potential donors, mostly 
when emotionally involved, are signiﬁ-
cantly more tolerant of risk acceptance, 
even if the risks are uncertain, because 
of the possibility of a beneﬁt to their 
relative. In this light, the capacity of 
medical professionals to investigate 
and to deﬁne the correct risk proﬁle of 
the potential donor appears crucial. The 
study by Young et al.6 aimed to deﬁne 
the tolerance of potential donors, recipi-
ents, and the transplant team for donor 
risk and their acceptance of donation 
in the presence of uncertain long-term 
risks. Particularly, the problem of an 
adequate ‘cooling-oﬀ ’ period needs to 
be addressed. Indeed, in many cases, 
the decision to become a donor is made 
at the peak of an altruistic wave, and it 
could involve an underestimation of 
the real risk–beneﬁt balance. From this 
point of view, transplant professionals 
must play a key role in education and, if 
it is possible, in supporting the potential 
donor’s decision.
In conclusion, living-donor kidney 
transplantation can help ease organ 
shortage, though it is not a complete 
solution. However, this therapeutic 
option needs a proper educational pro-
gram not only for potential donors and 
recipients, but also for transplant pro-
fessionals, making them aware of long-
term donor risks and conscious of the 
possibility that to refuse a donor could 
be a correct medical decision. On the 
other hand, it should be clear to the 
medical team involved in transplanta-
tion and to all nephrologists that living-
donor transplantation represents a real 
and eﬀective treatment possibility for 
end-stage renal disease.
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